NasdaqGS - Delayed Quote USD

Halozyme Therapeutics, Inc. (HALO)

53.31

-2.33

(-4.19%)

At close: June 3 at 4:00:01 PM EDT

53.49

+0.18

+(0.34%)

After hours: June 3 at 7:59:57 PM EDT

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 5 days ago

HALO
-4.19%
Halozyme to Participate at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences.

PR Newswire 6 days ago

HALO
-4.19%
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Zacks 6 days ago

HALO
-4.19%
Implied Volatility Surging for Halozyme Therapeutics Stock Options

Investors need to pay close attention to HALO stock based on the movements in the options market lately.

Zacks 6 days ago

HALO
-4.19%
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 6 days ago

HALO
-4.19%
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new Opdivo® (nivolumab) subcutaneous formulation developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following completion of intravenous nivolumab plus Yervoy® (ipilimumab) combination therapy, or in combination with chemothera

PR Newswire 6 days ago

HALO
-4.19%
High Growth Tech Stocks To Watch In The US May 2025

Over the last 7 days, the United States market has remained flat, but over the past 12 months, it has risen by 11% with earnings forecast to grow by 14% annually. In this context of steady growth and positive earnings outlooks, identifying high-growth tech stocks that align with these trends can be crucial for investors looking to capitalize on potential opportunities in this dynamic sector.

Simply Wall St. 6 days ago

LITE

COHR

HALO
-4.19%
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme

Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme have been highlighted in this Screen of The Week article.

Zacks 19 days ago

AXS

HALO
-4.19%

MOH
4 Stocks With Impressive Interest Coverage Ratio to Buy Now

STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships.

Zacks 20 days ago

AXS

HALO
-4.19%

MOH
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance

Shares of Halozyme Therapeutics (HALO) and Jonhson & Johnson (JNJ) are under pressure on Tuesday after Leerink downgraded the stocks to Underperform and Market Perform, respectively. This comes after the Centers for Medicare and Medicaid Services issued draft guidance for 2028 Inflation Reduction Act drug price controls, which the firm says creates risk that hyaluronidase combination products may not be protected from IRA price negotiations for 13 years after combo approval. DOWNGRADES ON CMS AC

TipRanks 20 days ago

HALO
-4.19%

JNJ
Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]

Insider Monkey 20 days ago

HALO
-4.19%

^GSPC
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products.

Investor's Business Daily 21 days ago

JNJ

BMY

CELG-RT
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 21 days ago

HALO
-4.19%
Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now?

We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against other unstoppable growth stocks to invest in now. BlackRock highlighted that the trade conflict between the US and China continues to cause major economic […]

Insider Monkey 22 days ago

HALO
-4.19%

^RUT

BLK
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Zacks 22 days ago

HALO
-4.19%
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 22 days ago

HALO
-4.19%
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points

Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.

Investor's Business Daily 24 days ago

RBRK

HALO
-4.19%

PODD
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 25 days ago

HALO
-4.19%
Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]

Insider Monkey 25 days ago

HALO
-4.19%
Halozyme Therapeutics First Quarter 2025 Earnings: Beats Expectations

Halozyme Therapeutics ( NASDAQ:HALO ) First Quarter 2025 Results Key Financial Results Revenue: US$264.9m (up 35% from...

Simply Wall St. 26 days ago

HALO
-4.19%

Performance Overview

Return	HALO	S&P 500 (^GSPC)
YTD	+11.50%	+1.51%
1-Year	+18.34%	+13.00%
3-Year	+16.86%	+45.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Halozyme Therapeutics, Inc. (HALO)

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Halozyme to Participate at Upcoming Investor Conferences

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

High Growth Tech Stocks To Watch In The US May 2025

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme

4 Stocks With Impressive Interest Coverage Ratio to Buy Now

Halozyme, J&J slide as analyst cuts rating on CMS draft guidance

Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?

Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now?

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?

Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Halozyme Therapeutics First Quarter 2025 Earnings: Beats Expectations

Performance Overview